CRTX NASDAQ
Cortexyme, Inc.
1W: -5.8%
1M: -13.7%
3M: -49.1%
1Y: -96.5%
3Y: -94.4%
$1.95
Last traded 2022-07-29 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$70.5M
52W Range—
Volume272,208
Avg Volume453,189
Beta1.40
Dividend—
Analyst Ratings
Company Info
CEOCasey Lynch
Employees55
SectorHealthcare
IndustryBiotechnology
IPO Date2019-05-09
Websitecortexyme.com
269 E Grand Ave
South San Francisco, CA 94080
US
South San Francisco, CA 94080
US
14159105717
About Cortexyme, Inc.
Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to pioneering new therapies for Alzheimer's and various other degenerative conditions. The company's primary investigational drug, atuzaginstat (also known as COR388), is an orally delivered, small molecule inhibitor engineered to cross the blood-brain barrier and target gingipain. This compound is currently in Phase II/III clinical trials, where it is being assessed for its potential use in individuals with mild to moderate Alzheimer's disease, as well as for tackling oral squamous cell carcinoma, periodontitis, and coronavirus infections. Established in 2012, Cortexyme, Inc. is headquartered in South San Francisco, California.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Monohon Ted | A-Award | 250,000 | — | 2022-06-29 |
| Bray June | A-Award | 54,000 | — | 2022-06-09 |
| Bray June | 0 | — | 2022-06-09 | |
| Senner Christopher J | A-Award | 27,000 | — | 2022-06-08 |
| RYAN UNA S | A-Award | 27,000 | — | 2022-06-08 |